Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
25.10.2026 07:30
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapyAn early median progression-free survival of 6.9 months was observedSignificant unmet need remains for patients who have progressed on an immunotherapy-containing regimen, with the average progression-free survival below 4 months for stan
The Call Bristol-Myers Squibb Bulls Got Right
25.10.2026 01:13
If you had been weighing Bristol-Myers Squibb against its looming patent cliffs and the promise of late-stage oncology drugs back in October 2025, the result now looks very different on paper. Holding Bristol-Myers Squibb over the past year would have returned 46.5%, including dividends. The question is simple: faced with aging demographics, genomics-driven treatments and debt concerns, what did early buyers think would matter most for this business? Narratives are how investors here put a...
Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access
24.10.2026 01:09
Bristol Myers Squibb (NYSE:BMY) has entered multi year AI drug development partnerships with Pathos AI and Tempus AI. The agreement gives Bristol Myers Squibb exclusive access to Pathos AI's discovery platform for neuroscience projects. Tempus AI will provide multi year data licensing that connects real world patient information with AI tools across Bristol Myers Squibb's pipeline. The company also launched a national collaboration with the Institute for Healthcare Improvement to broaden...
Sector Update: Healthcare Stocks Decline Friday Afternoon
23.10.2026 17:51
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index dropping 1.2% and the
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
23.10.2026 14:36
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
23.10.2026 14:30
PRINCETON, N.J., October 23, 2026--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients...
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
23.10.2026 13:00
NEW YORK, October 23, 2026--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors.
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
23.10.2026 13:00
CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest l
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
23.10.2026 13:00
NEW YORK, October 23, 2026--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and Tempus AI, Inc. (NASDAQ: TEM, "Tempus") to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio
3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street
23.10.2026 11:30
The recent AI sell-off shows why diversification matters. Here are three stocks that can help investors diversify their portfolios.
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
23.10.2026 11:30
BOTHELL, Wash. & PRINCETON, N.J., October 23, 2026--Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2-...
Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026
23.10.2026 10:33
Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating
Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Onco...
23.10.2026 09:11
Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected to state-of-the-art
SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026
23.10.2026 07:36
Late-breaking results to be presented in an oral presentation at ESMO 2026With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine treatment across breast
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
22.10.2026 11:30
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
22.10.2026 11:30
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
22.10.2026 11:13
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.
3 Unpopular Stocks We Keep Off Our Radar
20.10.2026 09:49
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
17.10.2026 01:10
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.